GSK returns gemifloxacin rights
Executive Summary
GlaxoSmithKline will return worldwide rights to quinolone antibiotic Factive (gemifloxacin) to development partner LG Chemicals Investments. Factive was deemed "not approvable" by FDA at the end of 2000 (1"The Pink Sheet" July 30, 2001, p. 20)...